Gefitinib-GEFISA®

Gefitinib-GEFISA®
Product Description

  • Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth.
  •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation.
  • Robust clinical studies confirm benefits in non-small cell lung and pancreatic cancers.
  • Delivered in tablet form for ease of use and enhanced patient adherence. Documented clinical benefits: Associated with notable improvements in progression-free survival and tumor response rates.
  • Supported by a wide array of peer-reviewed studies and clinical trials.
  • Adverse effects are well-characterized and can be effectively managed in clinical practice.

    • Read more Show less

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
      Oral film-coated tablet: 250 mg
    • Selling Points
    • Oral Formulation
    • Affordability
    • Proven Impact
    • Stringent Quality
  • Model
    250 mg
    • More specifications Fewer specifications

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile

    More Products from EXAMON Handelsges.m.b.H. (2)

    • Erlotinib-KIMOTAR®

      Product Erlotinib-KIMOTAR®

      • Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth. • Validated efficacy in non-small cell lung cancer (first-line). • Offered in tablet form to facilitate patient-friendly, outpatient treatment. • Underpinned by a wide range of peer-reviewed studies...
    • Imatinib

      Product Imatinib

      • Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...